Drug Type Monoclonal antibody |
Synonyms Anti-CA125-monoclonal-antibody-B43-13-AltaRex, Anti-idiotype-ovarian-cancer-vaccine-AltaRex, Anti-idiotype-ovarian-cancer-vaccine-CA125 + [7] |
Target |
Mechanism MUC16 inhibitors(Mucin-16 inhibitors), Dendritic cells stimulants(Dendritic cells stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (EU) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05269 | Oregovomab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 3 | TW | 27 Mar 2023 | |
Fallopian Tube Carcinoma | Phase 3 | US | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | US | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | AR | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | AR | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | BE | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | BE | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | BR | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | BR | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | CA | 25 Aug 2020 |
Phase 2 | Platinum-Sensitive Ovarian Carcinoma CA125 | STING | 10 | Oregovomab and Niraparib | oaxhahoijc(pdouqkmgcx) = gledhtepil rqdbzmmaxc (dgbwrsipwg ) View more | Positive | 24 May 2024 | |
Phase 2 | Ovarian Cancer First line | 97 | ombryekady(oyypfvnbgb) = irvqymtgnk rpaluenmif (homqrftkln, 21.8 ~ NE) View more | Positive | 01 Mar 2020 | ||
ombryekady(oyypfvnbgb) = cgdkwyjnsf rpaluenmif (homqrftkln, 10.4~18.6) View more | |||||||
Phase 2 | 11 | Stereotactic Body Radiation Therapy+Leucovorin Calcium+Gemcitabine Hydrochloride+Nelfinavir Mesylate+Oregovomab+fluorouracil | vnyinpivra(zvtrzvdgah) = wqyrehcswf sqylupbwdu (kkoeyayipt, fxmjhaizia - meavuimdqz) View more | - | 15 Nov 2019 | ||
NCT03100006 (ESMO2018) Manual | Phase 1 | Recurrent ovarian cancer Third line | 6 | swpxwaxcte(pkrqwvqhlh) = wmcubjtfbs xfzteoaifb (lrdddazqyf ) View more | Positive | 20 Oct 2018 | |
Phase 2 | Ovarian Cancer Consolidation | 145 | fdbeqwolfz(hqbqpsycug) = bucemecycu vqihgdtrya (khkizavekz, 44.5 - non to estimable) | - | 20 Jun 2006 | ||
Placebo | fdbeqwolfz(hqbqpsycug) = ambtrjsfnc vqihgdtrya (khkizavekz, 30.9 - non to estimable) | ||||||
Phase 3 | Ovarian Cancer Consolidation | 102 | (Group I) | zfjkompwsv(kbhfuobder) = gkjvbrxdud gnanijljet (inleszzytw ) View more | - | 01 Jun 2005 | |
(Group II) | zfjkompwsv(kbhfuobder) = pvkgohvzio gnanijljet (inleszzytw ) View more |